Dr. Georgescu is a physician entrepreneur with a unique blend of medicine, research and business experience. Recently, at InfoBionic, he has been part of the team that raised over $20M and cleared the remote cardiac monitoring device for arrhythmia detection both in the US and EU markets. Dr. Georgescu’s clinical background included working in cardiac catheterization and research laboratories at the University of Tokyo and Tufts Medical Center in Boston. His molecular and cellular biology, genetics, and animal and human studies, led to 11 peer-reviewed original articles and one book chapter. Dr. Georgescu is passionate about start-ups and helping new technologies come to life. He serves on the board of directors or advisory boards of several early-stage healthcare IT and medical device companies. Serban leads due diligence efforts and manages companies screening and the investment process at Massachusetts Medical Angels (MA2), a life sciences-focused angel investment group. Multilingual, with great international experience having lived and worked in Romania, Japan and USA, Dr. Georgescu is comfortable in any global environment. He earned his M.D. with honors from the Carol Davila University of Medicine and Pharmacy in Romania, and his MBA cum laude from Babson College.

Dr. Jeff Karp is an Associate Professor at Brigham and Women's Hospital, Harvard Medical School, and is Principal Faculty at the Harvard Stem Cell Institute and affiliate faculty at MIT through the Harvard-MIT Division of Health Sciences and Technology. His research harnesses materials science and stem cell biology to solve medical problems with emphasis on nanoscale/microscale materials and bio-inspired approaches. He has published more than 100 peer-reviewed papers and book chapters and has given over 160 national and international invited lectures and has 50 issued or pending patents. Several technologies that Dr. Karp has developed have formed the foundation for multiple products on the market and currently under development and for the launch of two companies, Gecko Biomedical and Skintifique. Dr. Karp's work has been recognized by CNN, NPR Science Fridays, Boston Globe, ABC News, MSNBC, Fox News, CBC Quirks and Quarks, CanadaAM, BBC, LA Times, Forbes, National Geographic, Popular Science, the Washington Post, the New York Post, and by Wired Magazine. In 2011 the Boston Business Journal recognized Dr. Karp as a Champion in Healthcare Innovation and in 2013 the Institute for Chemical Engineers (IChemE) awarded one of his technologies at the Most Innovative Product of the Year. In 2008 MIT’s Technology Review Magazine (TR35) also recognized Dr. Karp as being one of the top innovators in the world under the age of 35 (3 members from his laboratory have already received this award). He has received the Society for Biomaterials Young Investigator Award and his work has been selected as one of Popular Mechanic's "Top 20 New Biotech Breakthroughs that Will Change Medicine”. Dr. Karp was also elected in 2013 to the American Institute for Medical and Biological Engineering's College of Fellows and as a Kavli Fellow. In 2014 he gave a TEDMED talk on bioinspired medical innovation and in 2015 became a member of the TEDMED Editorial Advisory Board to help curate the stage program’s themes, topics, speakers and performers. Dr. Karp is also an acclaimed mentor. He was selected as the Outstanding Faculty Undergraduate Mentor among all Faculty at MIT and received the HST McMahon Mentoring award for being the top mentor among all faculty who mentor Harvard-MIT students. To date, 17 trainees from his laboratory have secured faculty positions at institutions throughout the world.

Frank is a seasoned physician-scientist and corporate strategist at the intersection of business, clinical medicine and basic research. He focuses on helping established and emerging biomedical companies, entrepreneurs, and investors unlock the financial and strategic value of innovative R&D. After studying molecular biophysics and biochemistry at Yale, Frank received his M.D. and Ph.D. degrees from Columbia University’s College of Physicians and Surgeons. A board-certified pathologist, he completed his clinical training at Brigham and Women’s Hospital, and then joined the faculty of Harvard Medical School and Brigham and Women’s, where he led an NIH-funded basic research group focused on cell signaling in cancer and kidney development. As Director in the consulting arm of Leerink Swann, a leading healthcare investment bank, Frank led advisory engagements for corporate, commercial, R&D, business development, and investor clients across all major therapeutic areas and business sectors, including biopharma, devices, diagnostics, life sciences tools, and healthcare services. He co-founded Leerink’s Transactional Consulting practice, which advised financial and strategic investors and early-stage companies side-by-side with Leerink's investment banking team. Frank’s strategic support of the Medical Publishing Insights and Practices (MPIP) initiative, a multi-pharma consortium to promote best practices in medical publishing, garnered Leerink the Communiqué Trust and Reputation Award in pharma communications. Prior to founding Pharmagellan, Frank was Director of Strategy in AstraZeneca’s Oncology Innovative Medicines unit, where he led business strategy efforts from target identification through Phase 2a. He spearheaded initiatives in end-to-end franchise strategy and portfolio valuation, led external communications focused on R&D collaborators and investors, and provided commercial support to pipeline projects and in-licensing teams. As a healthcare strategist, Frank has authored articles in Nature Reviews Drug Discovery, In Vivo, Pharmaceutical Executive, and Mayo Clinic Proceedings. He has been a speaker and panelist at the International Society of Medical Publication Professionals, the Council of Science Editors, Brigham and Women’s Hospital’s Innovation Grand Rounds, and Mass Bio. Frank also serves as Innovation Strategist at the Brigham Research Institute of Brigham and Women’s Hospital, and blogs for Forbes and on the Pharmagellan website.

Dr. Shaywitz is Senior Partner at Takeda Ventures, Inc., based in Palo Alto, where he focuses on early stage opportunities in life sciences as well as grounded, implementation-focused, tech-powered startups that can improve how impactful new treatments are discovered, evaluated, and delivered. Previously, Dr. Shaywitz was the Chief Medical Officer of DNAnexus, where he was responsible for driving translational impact and shaping company vision, working closely with the DNAnexus team of scientists and engineers, and with external partners and collaborators. Prior to that, at Theravance Biopharma, he focused on strategy, new product planning, and business development, and led a product team. Previously, he was a management consultant at the Boston Consulting Group, working with Top 5 Biopharma clients on both R&D and commercial engagements. Before that, he was an early member of the Department of Experimental Medicine at Merck Research Labs. Dr. Shaywitz was also a founding advisor of Sage Bionetworks, and a co-founder of the MGH/MIT Center for Assessment Technology and Continuous Health (CATCH). He has also served as a venture fellow at Fidelity Biosciences (now F-Prime Capital).  He graduated summa cum laude from Harvard, received his MD from the Harvard-MIT Division of Health, Science, and Technology at Harvard Medical School, and his PhD from the Department of Biology at MIT. He trained in internal medicine and endocrinology at the Massachusetts General Hospital, and conducted his post-doctoral research in Doug Melton’s lab at the Harvard Stem Cell Institute. He writes regularly for about medical innovation for Forbes, and contributes commentaries to a range of leading publications.  He is co-author, with Lisa Suennen, of “Tech Tonics: Can Passionate Entrepreneurs Heal Healthcare With Technology?,” and co-hosts, with Lisa Suennen, the twice-monthly Tech Tonics podcasts, focused on “the people and passion at the intersection of technology and health.

Annakaisa Niemi, MD, PhD, is a Clinical Instructor in the Department of Pediatrics, Divisions of Neonatology (primary), General Pediatrics and Medical Genetics at Stanford University. She is also a Co-Director of Pediatric Integrative Medicine (PIM) Residency program, a member of the Pediatric Integrative Medicine (IM) Core Group at Stanford Children's, and an Editor of the Metabolic Genetic chapters at PEMSoft/EBSCO. Dr. Niemi is the past Recipient of the Genzyme/ACMGF Clinical Genetics Fellowship in Biochemical Genetics Award (award period 7/2011-6/2012) and of the United Mitochondrial Diseases Foundation (UMDF) Clinical Fellowship Award (award period 8/2013-8/2014). Dr. Niemi's PhD thesis was on the role of mitochondrial DNA (mtDNA) in longevity and elite athletic performance. She has a special interest in Medical Biochemical Genetics, Medical Genetics, Pediatrics, Neonatology and Newborn Care, Integrative Medicine, Organ Transplants for Inborn Errors of Metabolism, and Palliative Care. Additionally, Dr. Niemi is active in blogging & writing (Facebook: Dr. AnnaKaisa, Twitter: @DrAnnakaisa). She has a special passion for creativity in science, medical education, making science & medicine understandable to everyone, children's & human rights, sustainability, and nature & outdoors.

Dr. Gruppuso received his B.A. in Fine Arts (Music) and his M.D. from the University of Rochester. Beginning with his residency in pediatrics, Dr. Gruppuso has spent the entirety of his career at Brown University and Rhode Island Hospital. Following a pediatric metabolism and endocrinology fellowship, he undertook postdoctoral training in the biochemistry. Dr. Gruppuso joined the Department of Pediatrics in 1987 as Director of the Division of Pediatric Endocrinology. He subsequently served as Vice-Chair of Pediatrics for Research and Director of Brown’s MD/PhD program. Dr. Gruppuso served as Brown’s Associate Dean for Medical Education from 2005 to 2013. He is a trainer for three of Brown’s graduate programs in biology. The recipient of continuous NIH support since 1989, Dr. Gruppuso’s research focuses on the regulation of normal and abnormal cellular growth using liver as a model tissue. His work relies on animal models, cell culture, and human tissue to study control of fetal growth, tissue regeneration, and tissue injury, including injury that can lead to cancer. The goal of his research is to understand how nutrition and other environmental factors affect cell growth, and to develop cell-based therapeutic approaches suitable for liver diseases. In recent years he has focused on the regulation of growth and signaling by the mTOR signaling pathway, a regulator of global translation, autophagy, ribosomal biogenesis, cell size, cell metabolism and gene expression. Among the more novel experimental approaches in use in our laboratory are the administration of drugs to developing rodent fetuses in situ, the profiling of the phosphoproteome from tissue, and the immuno-isolation of hepatic cells from developing liver and their transplantation into injured adult liver. Through the application of high-throughput genomic and proteomic methods to model animal systems, Dr. Gruppuso aims to gain insight into the physiology and pathophysiology of cellular growth regulation.

Dr. Klein is Chief, Department of Transfusion Medicine, and has been Special Assistant to the Director for science at the Warren G. Magnuson Clinical Center of the National Institutes of Health. Following his graduation from Harvard College, magna cum laude, Dr. Klein received his doctor of medicine from the Johns Hopkins School of Medicine in Baltimore, MD, and completed both his residency and hematology fellowship at The Johns Hopkins Hospital. He is Adjunct Professor of Medicine and Pathology at Johns Hopkins. Dr. Klein has authored or co-authored more than 250 publications pertaining to blood transfusion, including transfusion-transmitted disease, the management of immunosuppressive effects of blood transfusion, blood storage, and the impact of biotechnology on transfusion medicine. Dr. Klein is editor-in-chief emeritus of the Journal of Clinical Apheresis Associate Editor of Biologicals, and has served on the editorial board of Blood. He is currently an editor of Transfusion and The Journal of Translational Medicine. An active member of numerous professional societies, Dr. Klein has been a member of the Institute of Medicine Forum on Blood Safety, Chair of the US Pharmacopoeia Blood and Blood Products Committee, and currently chairs the American National Red Cross Medical Advisory Council and the WHO Blood Product Subcommittee of the Expert Committee on Biologic Standardization. He is a former Council President of the National Marrow Donor Program and Past President of the American Association of Blood Banks. He is a charter member of the US Secretary’s Advisory Committee on Blood Safety and Availability. Throughout his career, Dr. Klein has received numerous honors, including the NIH Clinical Center Director’s Award, the Emily Cooley Award of the American Association of Blood Banks, the Latham Award of the European Society of Hemapheresis, and the John B. Alsever Award for contributions to the blood banking sciences. The Public Health Service has awarded Dr. Klein the Commendation Medal, the Meritorious Service Medal, the NIH Director’s Award, and the Secretary’s Distinguished Service Award, the highest civilian award given by the Department of Health and Human Services.

A native New Yorker, Richard completed undergraduate studies at Yale and M.D./Ph.D. training at the University of Pennsylvania. Richard’s interest in immunology, autoimmunity, and apoptosis began at Penn during his Ph.D. when he worked with with Mark Green and John Reed studying the effects of the anti-apoptotic protein bcl-2 on T cell development. He trained in Internal Medicine and Rheumatology at Hospital of the University of Pennsylvania, and then moved to the NIH to do postdoctoral training 1996, where he worked in Michael Lenardo’s laboratory in NIAID studying the molecular basis of autoimmunity in the Autoimmune Lymphoproliferative Syndrome (ALPS). In 2001, Richard moved to the NIAMS IRP where he directs a lab focused on understanding the pathogenesis and treatment of autoimmune and inflammatory diseases at the molecular level, with the TNF family of cytokines as a special area of interest. Since 2010, in his role as Clinical Director, he directs the NIAMS IRP clinical research program, which comprises an ACGME-certified rheumatology fellowship training program, advanced training of physician-scientists, and managing natural history and experimental clinical trials in both rare and common rheumatic diseases. Outside of the lab, Richard enjoys playing the violin in the NIH Philharmonia and other venues, and spending time with family at home and abroad.

Craig Blackstone is Senior Investigator in the Neurogenetics Branch at the NINDS and Senior Advisor for the NIH MD-PhD Partnership Training Program. He received BS and MS degrees in 1987 from the University of Chicago, where he was awarded the Sigma Xi Award for Excellence in Undergraduate Research for his work with Dr. Donald F. Steiner. He was awarded a MSTP Fellowship at the Johns Hopkins University School of Medicine, where he completed MD and PhD degrees in 1994. His graduate studies in the laboratory of Dr. Richard Huganir were on the structure and regulation of glutamate receptors in the central nervous system, for which he received the David Israel Macht Research Award. After a neurology residency in the Harvard-Longwood Neurology Program, Dr. Blackstone pursued clinical fellowship training in movement disorders at the Massachusetts General Hospital and postdoctoral research training with Dr. Morgan Sheng at Harvard Medical School and MIT. In 2001, Dr. Blackstone joined the NINDS Clinical Neurosciences Program, where he continues to oversee an active neurogenetics clinic. His laboratory research focuses on the cellular and molecular mechanisms underlying inherited neurological disorders, particularly hereditary spastic paraplegias. He has served on the Executive Council of the American Neurological Association (ANA) and is currently Director of the ANA's Annual Translational and Clinical Research Course in the Neurosciences as well as Chair of the ANA's Wed Governance Committee. He is an elected member of the American Society for Clinical Investigation and serves on the Scientific Advisory Board of the Spastic Paraplegia Foundation, the Board of Consulting Editors for the Journal of Clinical Investigation, and the Editorial Board of Annals of Neurology. He served as Director of the NIH MD-PhD Partnership Training Program from 2011-2013. In 2012, Dr. Blackstone received the NIH Director's Ruth L. Kirschstein Mentoring Award, the NIH's highest mentoring honor.

Our lab has been studying the regulation of apoptosis during HIV infection and its treatment for a decade and a half. During that period, our group has made seminal observations including the first description that HIV upregulates FasL, HIV protease inhibitors are intrinsically antiapoptotic and can reduce apoptosis in animal models of non-HIV associated apoptosis, HIV infection dysregulates the TRAIL:TRAIL receptor system, as well as numerous studies on how HIV protease cleaves procaspase 8 to generate Casp8p41. In the current application, we intend to translate our deep understanding of the regulation of apoptosis during HIV infection to devise and test novel strategies for inducing latently HIV infected cells to undergo apoptosis following HIV reactivation.

Cynthia F. Bearer, MD, PhD is the Mary Gray Cobey Professor of Neonatology with tenure, Chief of the Division of Neonatology and Associate Chair for Research in the Department of Pediatrics, University of Maryland School of Medicine. Dr. Bearer is board certified in pediatrics and neonatal-perinatal medicine. She received her Ph.D. in biochemistry from Case Western Reserve University, her M.D. from the Johns Hopkins University. Dr. Bearer has published extensively on fetal and pediatric environmental health. She has been funded by NIH, CDC and U.S. EPA. Dr. Bearer is Editor-in-Chief elect of the journal, Pediatric Research with a 5 year term beginning January 1. She is Immediate Past Chair of the Board of the Children's Environmental Health Network and is a member of the American Pediatrics Society and the Society for Pediatric Research. She currently serves as the APS representative to the Pediatric Policy Council. She has served on the Committee to Evaluate Children’s Health of the National Academy of Science, the editorial board of Neurotoxicology, and on multiple study sections at the NIH. She is past President of the Fetal Alcohol Syndrome Study Group. She has been a member of the Scientific Advisory Board for the U.S. EPA and the Advisory Group to the Director of the National Center for Environmental Health at the CDC. She was recently awarded a Smith College Medal. Her major research interests are the effect of the environment and environmental chemicals on the development of the central nervous system.

Tracey L. Henry, MD, MPH, MS is a Health Policy Fellow at Georgetown University where she conducts health services research, provides primary care to the underserved populations in southeast DC and is a clinical preceptor/instructor. She obtained her MS in Neuroscience at Tulane University, MD at Georgetown University and a MPH from Johns Hopkins University in Health Systems and Policy. She completed her residency in Internal Medicine at Ochsner Clinic in New Orleans, LA where she served on the Lousiana State Medical Society Board of Governors and later received the Ochsner Alumni Association Outstanding Fellow and Resident Award and the 2013 American Medical Association (AMA)’s Paul Ambrose Award for Leadership Among Resident Physicians. Currently, she serves on the American College of Physician (ACP)’s National Council of Resident and Fellow members and the ACP’s National Health and Public Policy Committee. She was appointed by the AMA to serve on the Committee on Medical Education’s Accreditation Alignment Task Force for the 2014-2015 term and she serves on the National Board of Medical Examiners. Her research interests include health disparities, primary care and behavioral health integration and the physician workforce. In her spare time she enjoys photography, traveling, movies/theater and spending times with family and friends.

Dr. Ann Berger completed her undergraduate degree with a B.S. in nursing from New York University, which was then followed by receiving a MSN in Oncology Nursing from University of Pennsylvania. After working as an Oncology Clinical Nurse Specialist for several years, Dr. Berger completed her medical training at Medical College of Ohio in Toledo, Ohio. Following medical school, Dr. Berger completed an internship and residency at Hartford Hospital in Connecticut and a Fellowship in medical oncology and pain/palliative care at Yale University in Connecticut. Dr. Berger remained on the faculty at Yale University where she started a palliative care service, as an Assistant Professor in Medicine and Anesthesiology. As an Assistant Professor in medicine and anesthesiology at Cooper Hospital/University Medicine and Dentistry in New Jersey, Dr. Berger founded her second successful palliative care service. There, her service was actively involved in the care of patients and in education and research during her four year tenure. She initiated a palliative care course to medical students, residents and Fellows, and utilized her expertise while chairing the ethics committee. Dr. Berger also served as Medical Director of Lighthouse Hospice and as Director of Supportive Care Services at Cooper Hospital/University Medicine and Dentistry in New Jersey. During this time she also received two grants as Project Director of a pain and palliative care scholars program, and as Project Director for a project designed to develop pain/palliative care teams in New Jersey long term care facilities. Currently, Dr. Berger is chief of the Pain and Palliative Care Service at the National Institutes of Health, Clinical Center, where she has clinical, teaching, research, and administrative responsibilities. Nationally, Dr. Berger has been involved with many activities including chair of the National Institutes of Health Clinical Center Pain and Palliative Care Collaborative Working Group, member of the steering committee for the National Palliative Care Consensus Project, and has been on the planning committee to improve quality of end of life care in conjunction with the Washington Area Geriatric Education, RAND Center to improve care of the dying, and DC Partnership to improve end of life care. On a community level Dr. Berger is a co-facilitator of a healing service at her synagogue. Internationally, she has been involved in the All-Ireland Fatigue Coalition, the Mid-Eastern Cancer Consortium, and the Croatian cancer consortium. In 1998 Dr. Berger received the Hospice Medical Director Award, and in 1999 she was awarded the Spirit of Hospice Award from New Jersey Hospice and Palliative Care Organization. In 1998-2000, Dr. Berger was awarded an award for outstanding leadership in palliative care in long term care from the NJ SEED project, NJ Dept. of Health and Senior Services, Office of the Ombudsman for the Institutionalized Elderly and the Cooper Health Service. In the year 2001, Dr. Berger was awarded the directors clinical center patient care award at the National Institutes of Health. In 2002 Dr. Berger was awarded the Circle of Excellence award from Samaritan Hospice, as well as a proclamation from the New Jersey State Senate and Legislative Committees. She has lectured and published extensively in pain and palliative care. Dr. Berger is Senior Editor of the major palliative care textbook, Principles and Practice of Supportive Oncology, published by Lippincott-Raven in 1998, as well as senior editor of Principles and Practice of Palliative Care and Supportive Oncology, , second, third edition last published in 2006, and the 4th edition published in 2013. . . Since 2004 Dr. Berger had several new books published: Cancer Pain: A Bedside Approach, Chemotherapy-induced Nausea and Vomiting, Handbook of Supportive Oncology- all three for health care professionals, and Myths and Facts of Cancer Fatigue for the patient with cancer as well as Myths and Facts about Chronic and Cancer Pain published. Dr. Berger has also published first book for lay people Healing Pain- by Rodale.

Dr. Fabio Benedetti, MD, was appointed Taiho Oncology, Inc’s Senior Vice President and Chief Medical Officer in March 2010. Dr. Benedetti has extensive experience in oncology, ranging from medical practice to clinical drug development and medical affairs. Prior to joining the company, he has served in various leadership positions including Senior Vice President and Chief Medical Officer of Oncology at Geron Corporation, Vice President of Medical Affairs at Onyx as well as Millennium Pharmaceuticals, and has held Medical Director level positions at Bristol-Myers Squibb and Roche Laboratories. Dr. Benedetti graduated from Brown University, where he also went on to receive his medical degree in 1990. After finishing his Internal Medicine residency at Strong-Memorial Hospital in Rochester, NY, he went on to complete a Medical Oncology/Hematology fellowship at the Memorial Sloan-Kettering Cancer Center in New York City, where he subsequently worked as an Attending Physician for the Gastrointestinal Oncology Service.

I am a physician scientist who directs basic and translational research in the laboratory. I also perform clinical service work in Neuropathology. This activity includes teaching residents and students. My research efforts are mainly focused on understanding the role of insulin and insulin-like growth factor resistance in relation to neurodegeneration caused by Alzheimer's disease and chronic alcohol abuse.

Dr. Hertzano is an assistant professor of Otolaryngology-Head and Neck Surgery at the University of Maryland School of Medicine. Dr. Hertzano received her medical and Ph.D. degrees from Tel Aviv University, where she studied the molecular basis of hearing impairment and was the recipient of a Foulkes Foundation Fellowship physician-scientist award. She completed her internship and residency in the Department of Otorhinolaryngology-Head & Neck Surgery at the University of Maryland School of Medicine. During residency training she established a collaborative research group named the Laboratory of Inner Ear Developmental Genetics (LIEDG, see below). The focus of Dr. Hertzano’s basic science research is on understanding the molecular mechanisms leading to inner ear development as well as acquired hearing loss, using genomic, cell type-specific approaches. In 2014 Dr. Hertzano was the recipient of the National Organization of Hearing Research Burt Evans Young Investigator Award, for dedicated commitment and excellence in the pursuit of auditory neuroscience. Dr. Hertzano is a surgeon-scientist and her clinical practice is focused on diseases of the ear and lateral skull base, with a particular interest in hearing restoration and genetic hearing loss. As part of her clinical practice, she is developing a comprehensive interdisciplinary genetic hearing loss service at the University of Maryland. Dr. Hertzano has a specific interest in mentoring both graduate and medical students.

Dr. Meagher serves as Associate Professor of Medicine and Pharmacology at the University of Pennsylvania Perelman School of Medicine in Philadelphia, PA. She is Program Director of the Masters of Science in Translational Research (MTR), Course Director of Pharmacology for the Perelman School of Medicine, Associate Vice Provost for Human Subjects Research, Senior Associate Dean for Clinical Research and Chief Clinical Research Officer. She graduated cum laude with a medical doctorate degree from the Royal College of Surgeons in Dublin, Ireland. Following completion of an internship and residency in internal medicine she was appointed as Senior Registrar/Lecturer of Cardiovascular Medicine at Mater Hospital, University College in Dublin, Ireland. She emigrated to the US in 1994 with her husband and four children. Dr. Meagher’s educational interests are in the fields of translational research methodology to graduate, pre- and post-doctoral students and novel modalities for education in pharmacology to undergraduate medical (UME) students. To this end she directs the University of Pennsylvania pharmacology curriculum, is Program Director for the MTR and Co I of the UPenn Clinical and Translational Sciences Award (CTSA). Dr. Meagher’s research interest is the development of novel therapeutics in dyslipidemia. Her clinical practice is focused on cardiovascular risk modification with an emphasis on management of dyslipidemia, hypertension and women’s cardiovascular health. Dr. Meagher has published articles in numerous journals, including Nature Medicine, the Journal of Clinical Investigation, JAMA, The Journal of Biological Chemistry, The American Journal of Cardiology, Hypertension and the Journal of Cardiovascular Pharmacology. She has written numerous reviews and book chapters, and has lectured widely at medical meetings, both nationally and internationally.

Dr. Gideon Koren is interested in understanding the pathogenesis of cardiac arrhythmias through three main lines of investigation: 1) Genomic studies to elucidate the transcriptional program(s) that control the expression of membrane polypeptides involved in determining the duration of cardiac action potential and early and late afterdepolarizations, as well as the aging of the heart. As part of these studies Dr. Koren is interested in studying the differentiation and senescence of adult cardiac stem cells; 2) Investigation of the trafficking and localization of voltage-gated potassium channels in the cardiomyocytes; and 3) Creation of genetically modified animal models for studying sudden cardiac death. Dr. Koren's laboratory is also focusing on the molecular mechanisms underlying the trafficking post translational modifications and turnover of Kv1.5 and KV2.1 potassium channels in the heart and protein interactions between HERG and KCNQ1. His group is characterizing the macromolecular complex (channelosome) that modulates the localization and function of several delayed rectifier potassium channels in the heart. In addition, his laboratory has analyzed and compared the phenotype of two novel transgenic rabbit models of long QT syndrome 1and 2 (LQT1 and LQT2) using surface ECG; monitoring of alert, free-moving rabbits, programmed electrical stimulation (PES) of the right ventricle of anesthetized rabbits, and analyses of the biochemical and electrophysiological phenotype of rabbit cardiomyocytes derived from the epicardial, mid-myocardial, and endocardial layers of the left ventricle.

Dr. Dorothea McAreavey is a cardiologist and intensivist with the Critical Care Medicine Department and also serves as Program Director for the Critical Care Medicine Fellowship Program. She provides nuclear cardiology services with the Nuclear Medicine Department at the NIH Clinical Center. Other appointments include adjunct associate professor in the Department of Anesthesiology at the University of Maryland in Baltimore. She completed her undergraduate and medical degrees at Queens University in Belfast, Northern Ireland. She joined NIH in 1991 as a visiting scientist and later as a senior staff fellow in the Cardiology Branch of the National Heart, Lung, and Blood Institute. In 1998, she joined the CC Critical Care Medicine Department as a fellow and was appointed to her current position in 2001.

Psychiatric illness remains one of the last great frontiers in medicine. Despite incredible advanced in technology over the past decades, including new genetic analyses, blood tests and imaging, an objective laboratory test for psychiatric illness has yet to be developed. The bulk of research to date has been valuable insofar as it has helped reduce the social stigma of psychiatric illness, as distinct chemical and imaging signature of psychiatric illness have found group differences between people with psychiatric symptoms and people without (e.g., healthy controls). However, none of these tests to date have been strong enough to diagnose individual patients. A paradigm shift is needed. My lab is dedicated to developing new MR-based imaging tools for the diagnosis and management of psychiatric illness. To date we have explored phosphorus and lithium imaging and spectroscopy, as well as more traditional proton-based imaging and spectroscopy. Our goal is to develop at least one MR-based tool that can make a definitive diagnosis of psychiatric disease in the individual patient.

Dr. Chan received his B.A. degree from Dartmouth College, Hanover, New Hampshire, with a major in political science. He graduated from the UCLA School of Medicine in 1990. Chan then completed postgraduate training in Physical Medicine and Rehabilitation at the University of Washington. During his training, he also obtained a Master of Science degree in rehabilitation science. Subsequently, he completed a Robert Wood Johnson Clinical Scholar Fellowship, earned a master of public health degree at the University of Washington School of Public Health and was a Congressional Fellow for the Honorable Jim McDermott (Washington). From 1994 to 2006, Dr. Chan was on the faculty of the University of Washington's Department of Rehabilitation Medicine. He is board certified in Physical Medicine and Rehabilitation. Dr. Chan's research interests include health services research, quality of care given to individuals with disabilities, and Medicare payment policy issues. He has published more than 100 peer reviewed articles and numerous book chapters.

Dr. Jensen received his M.D. from the University of Missouri – Kansas City and completed his residency in internal medicine and subspecialty training in endocrinology & metabolism at Mayo Clinic, Rochester, MN. He is currently the director of the Obesity Treatment Research Program at Mayo Clinic and maintains an active research program focusing on obesity-related pathophysiology in humans. He holds the Tomas J. Watson, Jr. Professorship in Honor of Dr. Robert L. Frye at the Mayo College of Medicine. His clinical interests are primarily focused on obesity and diabetes. Dr. Jensen's research involves the study of body fat distribution, and fatty acid/energy metabolism, focusing specifically on the effects obesity and body-fat distribution on health. His studies have identified the relative contributions of different fat depots to lipid fuel metabolism, including the role of intra-abdominal fat. He received a MERIT award from NIH to support his studies in this area and has been funded for 27 consecutive years. He has served on NIH, professional foundation and Mayo scientific review panels and has contributed to professional associations both by committee work and in elected office. Dr. Jensen has published more than 230 original research articles, together with over 50 invited papers and book chapters. He has served on the editorial boards of Obesity Research, American Journal of Physiology: Endocrinology and Metabolism, Diabetes, Obesity, and is currently senior associate editor of Diabetes. Dr. Jensen served as co-chair of the NHLBI Expert Panel on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults, 2008-2013.